Alflutinib Mesylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Alflutinib Mesylate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Alflutinib Mesylate can convert its Small molecule drug profile and EGFR L858R x EGFR T790M x EGFR exon 20 x EGFR-Ex19del biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Alflutinib Mesylate (query alias: Alflutinib Mesylate) |
|---|---|
| Modality / target | Small molecule drug; EGFR L858R x EGFR T790M x EGFR exon 20 x EGFR-Ex19del; EGFR T790M inhibitors, EGFR exon 19 deletion inhibitors, EGFR exon 20 inhibitors |
| Highest global status | Approved |
| Originator | Shanghai Allist Pharmaceuticals Co., Ltd. |
| Active developers | Shanghai Allist Pharmaceuticals Co., Ltd., Arrivent BioPharma, Inc. |
The MCP disease footprint includes EGFR ex20ins mutation in non-small cell lung cancer, EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer, EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07661173 | Phase 2 | Not yet recruiting | 154 | Progression-free survival (PFS) |
| ChiCTR2600127967 | Phase 2 | Not yet recruiting | 39 | Objective response rate (ORR) |
| NCT07655622 | Phase 1/2 | Recruiting | 45 | Phase Ib: Incidence of Dose-Limiting Toxicities as assessed by protocol-defined criteria and CTCAE v5.0 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Firmonertinib combined with cisplatin/carboplatin plus pemetrexed as neoadjuvant therapy in resectable stage II-IIIb EGFR-mutated non–small cell lung cancer: A single-arm, single-center, open-label phase II study.
Phase 2; n=13; evaluation: Positive. Reported fields: ORR = 77.8 %
High-dose furmonertinib in EGFR-mutated advanced NSCLC with brain metastases after EGFR-TKI resistance: The iFORCE phase II trial.
Phase 2; n=23; evaluation: Positive. Reported fields: Adverse Event: stomatitis = one patient (4.3%) experienced a grade 3 stomatitis
High-dose furmonertinib in EGFR-mutant NSCLC with brain metastases after EGFR-TKI resistance.
Not Applicable; n=285; evaluation: Positive. Reported fields: CR = 4.0 % ( 1 - 10)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Alflutinib Mesylate addresses EGFR ex20ins mutation in non-small cell lung cancer, EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer, EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-07-10 | 上海艾力斯医药科技股份有限公司收到江苏复星医药关于磺酸伏美替尼片独家许可协议仲裁请求通知 | Approved | Financial terms not disclosed |
| 2021-06-30 | ArriVent partners with Allist to globally develop and market furmonertinib for cancers, excluding Mainland China and Hong Kong, Macao, and Taiwan. | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
